Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome
0301 basic medicine
QH301-705.5
Induced Pluripotent Stem Cells
Mutation, Missense
610
Genes, Recessive
Polymerization
Humans
Myocytes, Cardiac
Biology (General)
info:eu-repo/classification/ddc/610
0303 health sciences
Noonan Syndrome
Cardiomyopathy, Hypertrophic
CP: Metabolism
Phenotype
Mutation
Proteolysis
CP: Cell biology
ras Proteins
Technology Platforms
Genes, Cells and Cell-Based Medicine [Topic 1]
CRISPR-Cas Systems
Protein Multimerization
Transcription Factors
DOI:
10.1016/j.celrep.2024.114448
Publication Date:
2024-07-13T05:04:18Z
AUTHORS (21)
ABSTRACT
Published by Cell Press, Maryland Heights, MO<br/>Noonan syndrome patients harboring causative variants in LZTR1 are particularly at risk to develop severe and early-onset hypertrophic cardiomyopathy. In this study, we investigate the mechanistic consequences of a homozygous variant LZTR1L580P by using patient-specific and CRISPR-Cas9-corrected induced pluripotent stem cell (iPSC) cardiomyocytes. Molecular, cellular, and functional phenotyping in combination with in silico prediction identify an LZTR1L580P-specific disease mechanism provoking cardiac hypertrophy. The variant is predicted to alter the binding affinity of the dimerization domains facilitating the formation of linear LZTR1 polymers. LZTR1 complex dysfunction results in the accumulation of RAS GTPases, thereby provoking global pathological changes of the proteomic landscape ultimately leading to cellular hypertrophy. Furthermore, our data show that cardiomyocyte-specific MRAS degradation is mediated by LZTR1 via non-proteasomal pathways, whereas RIT1 degradation is mediated by both LZTR1-dependent and LZTR1-independent pathways. Uni- or biallelic genetic correction of the LZTR1L580P missense variant rescues the molecular and cellular disease phenotype, providing proof of concept for CRISPR-based therapies.<br/>Cell reports 43(7), 114448 - (2024). doi:10.1016/j.celrep.2024.114448<br/>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....